Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity

Rhea-AI Summary

Cardiff Oncology (Nasdaq: CRDF) will host a key opinion leader webinar on April 30, 2026 at 11:00 a.m. ET to discuss investigator-initiated trial data showing single-agent activity of onvansertib in chronic myelomonocytic leukemia (CMML).

Registration and live webcast access are available via the company Events page; a replay will be posted after the discussion.

Market Context

This announcement centers on a KOL webinar to discuss single-agent onvansertib activity in CMML, add...

Analysis

This announcement centers on a KOL webinar to discuss single-agent onvansertib activity in CMML, adding another touchpoint in Cardiff Oncology’s communication of its PLK1 program. In recent months, the company has highlighted clinical data, preclinical findings and leadership changes. Investors evaluating this update may focus on the specific CMML data discussed, any indication of future development plans, and how these complement prior colorectal and breast cancer work with onvansertib.

Key Figures

KOL webinar time: April 30, 2026, 11:00 a.m. ET

1 metrics

KOL webinar time April 30, 2026, 11:00 a.m. ET Onvansertib single-agent CMML webinar

Historical Context

5 past events · Latest: Apr 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 21	Clinical conference update	Positive	-7.3%	Announcement of updated Phase 2 onvansertib data to be presented at ASCO 2026.
Apr 17	Preclinical data update	Positive	-1.1%	AACR 2026 data showing onvansertib potentiating HER2-targeted ADC in breast cancer models.
Apr 09	Leadership changes	Positive	-5.4%	Appointment of new CEO, CFO and COO to drive next phase of growth.
Mar 20	KOL webinar	Positive	-1.1%	Announcement of KOL webinar on first-line RAS-mutated mCRC data and positioning.
Mar 19	Preclinical data update	Positive	+0.6%	AACR 2026 poster on onvansertib enhancing antitumor activity in HER2-low breast cancer models.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent seemingly positive clinical and corporate updates have often been followed by negative or muted next-day price reactions, suggesting a pattern of skepticism or selling into news.

Recent Company History

Over the past months, Cardiff Oncology has focused on advancing onvansertib and reshaping leadership. Clinical and preclinical updates at AACR and ASCO, plus KOL events, highlight ongoing development in metastatic colorectal cancer and breast cancer models. Leadership changes and new executive compensation structures were disclosed in multiple filings and 8-Ks. Despite this, several prior news days saw negative price reactions, framing today’s CMML-focused KOL webinar as part of a broader, sustained communication push.

Key Terms

plk1 inhibition, chronic myelomonocytic leukemia (cmml), epigenetics, epigenomics, +1 more

5 terms

plk1 inhibition medical

"a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies"

PLK1 inhibition means blocking the activity of the enzyme Polo‑like kinase 1, a protein that helps cells divide. For investors, it signals a drug approach aimed at slowing or stopping fast‑growing tumors by disrupting the cell’s “division machinery,” but it also raises safety and trial‑success questions because the same process is important in healthy tissues; clinical results and side‑effect profiles drive the investment impact.

chronic myelomonocytic leukemia (cmml) medical

"single-agent clinical activity in chronic myelomonocytic leukemia (CMML)."

A rare type of blood cancer in which the bone marrow produces too many abnormal white blood cells and not enough healthy ones, leading to fatigue, infections, and bleeding; think of the bone marrow as a factory making faulty products. It matters to investors because it drives demand for diagnostics, treatments and clinical trials, and regulatory approvals or new therapies can significantly affect the revenues and valuation of healthcare companies involved.

epigenetics medical

"interests lie in precision genomics and epigenetics and the application of the same"

Epigenetics is the study of how environmental factors and experiences can influence how genes are turned on or off without changing the underlying genetic code. Think of it like a dimmer switch for a light, adjusting the brightness without altering the bulb itself. This process can affect health, behavior, and even how diseases develop, which is important for investors interested in long-term trends in medicine, wellness, and biotech industries.

epigenomics medical

"Scientific Director of the Epigenetics Developmental Laboratory and the Epigenomics Program."

Epigenomics is the study of chemical marks and patterns across the genome that turn genes on or off without changing the DNA sequence, like software switches controlling the same hardware. For investors, epigenomic discoveries can point to new drug targets, diagnostics, or ways to predict who will benefit from a therapy, affecting a biotech’s potential revenue, development risk and market value.

clonal hematopoiesis medical

"He directs the Mayo Clinic Clonal hematopoiesis Clinic (CHIP), bone marrow failure"

Clonal hematopoiesis is a common, age‑related condition in which certain blood stem cells acquire DNA changes and produce a larger share of circulating blood cells, like a few trees in a forest growing taller than the rest. It matters to investors because those altered blood cell clones are linked to higher risk of blood cancers and heart disease, can skew blood‑based tests, and influence drug safety and the market for diagnostics and therapies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the Company will host a key opinion leader (KOL) webinar to discuss data from an investigator-initiated trial on onvansertib's single-agent clinical activity in chronic myelomonocytic leukemia (CMML). The webinar will take place on Thursday, April 30th, 2026, at 11:00 a.m. ET.

The webinar will feature KOL Mrinal Patnaik, MBBS, a physician scientist with the Division of Hematology, Department of Internal Medicine at Mayo Clinic, Minnesota. He is the Chair of the Acute Leukemia and Myeloid Neoplasms group at Mayo Clinic, Rochester and is also the Scientific Director of the Epigenetics Developmental Laboratory and the Epigenomics Program. His main clinical and research interests lie in precision genomics and epigenetics and the application of the same to myeloid neoplasms and bone marrow failure syndromes. He directs the Mayo Clinic Clonal hematopoiesis Clinic (CHIP), bone marrow failure syndrome clinic and the short telomere clinic.

KOL Webinar Information

Interested parties can register for and access the live webcast by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the discussion.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (“mCRC”), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

For more information, please visit https://www.cardiffoncology.com.

Investor Contact: 
Candice Masse 
Astr Partners 
candice.masse@astrpartners.com

Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com

FAQ

When is the Cardiff Oncology (CRDF) KOL webinar on onvansertib data?

The webinar is scheduled for April 30, 2026 at 11:00 a.m. ET. According to the company, the live webcast can be accessed via Cardiff Oncology's Events page and a replay will be available after the presentation concludes.

Who is presenting the onvansertib investigator-initiated trial results at the CRDF webinar?

The presentation will feature KOL Mrinal Patnaik, MBBS, a Mayo Clinic physician scientist. According to the company, he will discuss single-agent clinical activity of onvansertib in CMML and related precision genomics and epigenetics context.

How can investors register for the Cardiff Oncology (CRDF) onvansertib webcast?

Investors can register via the Cardiff Oncology website Events section for the live webcast. According to the company, registered attendees gain live access and a replay will be posted after the discussion for later viewing.

What topic will the CRDF webinar focus on regarding onvansertib?

The webinar will focus on investigator-initiated trial data showing single-agent activity of onvansertib in CMML. According to the company, the discussion will cover clinical activity and relevant precision genomics and epigenetics implications.

Will a replay of the Cardiff Oncology (CRDF) onvansertib webinar be available?

Yes, a replay will be available after the live event concludes. According to the company, the webcast replay will be posted on Cardiff Oncology's website for registered and later viewers.